
The Prototype: New Bacteria Discovered On Chinese Space Station
In this week's edition of The Prototype, we look at whether we should worry about spaceborne bacteria, a clinical trial for regenerating nerves after a traumatic injury, a new class of electronics and more. You can sign up to get The Prototype in your inbox here.
A Chinese spacecraft returning from the Tiangong space station
A previously unknown strain of bacteria is living on Chain's Tiangong space station, according to a study published this week. The new microorganisms were discovered on swabs taken from the station. The news immediately brought the novel (and movie) The Andromeda Strain into my brain, which is about a disease that makes it to Earth from space by way of a government satellite.
Luckily, Amesh Adalja, a senior scholar at the Johns Hopkins Center for Health Security, reassured me that any microorganisms found in space aren't likely to cause a new pandemic. 'It's important to remember that the vast, vast majority of bacterial organisms are not going to cause any harm,' he said.
One thing to consider about these types of microbes, he said, is that their ability to adapt to one extreme environment does not mean they will thrive in another environment that it's not adapted to.' And to determine whether such an organism might pose a disease risk, it's important to consider whether they can survive in human bodies. If they can, do they even cause any harm? Odds are, they don't, he said. 'Most bacteria that live on or in us aren't harmful,' he said.
Even if a new microorganism adapted to space or some other environment were to cause disease, humans still wouldn't necessarily be helpless, Adalja said. That's because lots of microorganisms share characteristics with each other, meaning the study of a new pathogen's data, like its DNA, can help researchers determine ways to find a treatment or vaccine.
Stay tuned.
Auxilium Biotechnologies
Over 300,000 people every year experience an accident that causes damage to their peripheral nerves–those that exist outside of the brain and spinal cord. These injuries can be serious and lead to disability in some cases. There's no easy way to treat them, either. When repairs are possible, they often require surgically grafting a portion of a healthy nerve from another part of the body to the injured one. Sometimes that canlead to difficult complications and side effects like chronic pain.
San Diego-based Auxilium Biotechnologies has a different approach. It's developed a device it calls a NeuroSpan Bridge, which it hopes will enable damaged nerves to regenerate into health. It does this by physically guiding the nerves to grow in a single direction to repair the damage. The company announced this week that it will begin a clinical trial of 80 nerve trauma patients with its device.
Nerves do actually regenerate naturally, CEO and cofounder Jacob Koffler, who is also a professor of neuroscience at UC San Diego, told me. But the problem is that 'the nerve goes wherever it wants,' he said. It doesn't necessarily reconnect with the rest of the healthy nerve. 'What we bring to the table is a technology that organizes regeneration' by guiding the regenerated nerves directly to the healthy one. The company has already successfully demonstrated the device in mice, so humans are the next step.
The clinical trial will take about a year, Koffler said. If results are good, the company would then work to seek a green light from the FDA to commercialize its device.
Scientists at Rutgers University have created 'intercrystals' - a new substance that could power the electronics of the future. It consists of two layers of graphene, each one atom thick, which are laid on top of a crystal made from boron and nitrogen. The result is a structural pattern in the chemistry that allows a very efficient transmission of electrons that can be refined on the atomic level. The researchers behind the discovery say it could someday lead to more efficient electronics materials such as sensors or transistors. Even more importantly–all the components are cheap. 'Because these structures can be made out of abundant, non-toxic elements such as carbon, boron and nitrogen, rather than rare earth elements, they also offer a more sustainable and scalable pathway for future technologies,' researcher Eva Andrei said in a press release about the discovery.
NASA says that a 'cumulative multi-year budget reduction' will force cutbacks in crew size and scientific research on board the International Space Station. NASA is currently considering operating the U.S. portion of the station with a three person crew, rather than four. There are also fewer planned cargo flights to the International Space Station, which will reduce revenues for contractors like SpaceX and Northrop Grumman. It's not clear yet whether NASA will be able to continue to support private missions to the ISS, such as those from SpaceX purchased by Axiom Space.
I wrote about Abel Avellan, whose company AST SpaceMobile is taking on SpaceX and Jeff Bezos' Project Kuiper in the battle to provide broadband satellite internet directly to your smartphone. This would enable connectivity in remote areas and help the over 2.6 billion people who currently lack regular internet access o get online.
In my other newsletter, InnovationRx, Amy Feldman and I looked at the FDA's new COVID-19 vaccine rules, Novartis's acquisition strategy, Medtronic's diabetes spinoff, Regeneron's purchase of 23AndMe, and more.
Recycling electronics might get easier thanks to researchers at the University of Helsinki, who figured out a way to extract silver from old electronics with used cooking oil.
Funding for scientific research is at its lowest point in 35 years, reports the New York Times, with nearly every field being impacted by the slowdown in grants from the National Science Foundation.
Energy infrastructure projects tend to be over budget and behind schedule, a new study finds. Nuclear power plants are the worst offenders. If you want the best bang for your energy investment buck, build a solar power project–they tend to finish under budget or ahead of schedule.
Researchers built a new kind of lithium battery that works by pulling carbon dioxide out of the atmosphere. Previous attempts at this kind of chemistry tended to be expensive and not work well, but the new version could allow them to scale cheaply. And good news for Elon Musk–they're ideal for Mars, where the atmosphere is 95% carbon dioxide.
One of the downfalls of restrictive dieting to lose weight is that pretty soon you start craving certain foods–and once you give in after prolonged abstinence, you may start binging, which can derail your diet completely. A new study suggests a better way: eat what you crave. During the study, a group of people on a diet were encouraged to include the foods they love, even junk food, into otherwise balanced meals. That group of people not only lost more weight, they also reported fewer food cravings than those who didn't incorporate such foods into their meal plans.
One of the comforts of the streaming era is the chance to finally get around to shows that you missed the first time. Right now, for example, I'm watching Boardwalk Empire, which aired on HBO from 2009 to 2014. The series is centered on organized crime and corruption in Atlantic City during the Prohibition era, using real-life characters like Al Capone, Lucky Luciano and Meyer Lansky. Steve Buscemi is excellent in the lead role and it's a great watch for anyone who's into a good mob drama. All episodes are streaming on Max–or HBO Max–or whatever we're calling it now.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
18 minutes ago
- Medscape
Tocilizumab, Alone or With Methotrexate, Potent in Active RA
Subcutaneous tocilizumab, either as monotherapy or in combination with methotrexate, demonstrated greater efficacy than methotrexate alone and was well tolerated in patients with active rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). METHODOLOGY: Researchers conducted a phase 3 trial at 19 sites in China between July 2017 and August 2022 to evaluate the efficacy of subcutaneous tocilizumab, administered either as monotherapy or in combination with methotrexate, in 340 patients with moderate to severe active RA (mean age, 47.5 years; 86.5% women). The patients had a diagnosis of RA for ≥ 6 months, had received methotrexate for ≥ 12 weeks, experienced treatment failure with at least one csDMARD (including methotrexate), had at least six swollen joints and at least eight tender joints, and had either a high-sensitivity C-reactive protein level ≥ 4 mg/L or an erythrocyte sedimentation rate ≥ 28 mm/h. Patients were randomly assigned to receive tocilizumab-methotrexate combination therapy (n = 136), tocilizumab monotherapy with placebo (n = 136), or methotrexate monotherapy with placebo (n = 68) for 24 weeks. Tocilizumab (162 mg) was administered subcutaneously once every 2 weeks, and methotrexate (10-25 mg) was administered orally once every week. Patients achieving a Disease Activity Score in 28 joints of ≤ 3.2 after 24 weeks continued their randomly assigned treatment, whereas those with a score > 3.2 switched to unblinded tocilizumab-methotrexate treatment. The primary efficacy endpoint was the proportion of patients who achieved a ≥ 20% improvement in the American College of Rheumatology (ACR20) response criteria at 24 weeks, with long-term efficacy analyzed at 48 weeks and safety monitored for 56 weeks. TAKEAWAY: The ACR20 response rate at 24 weeks was higher in the tocilizumab-methotrexate combination therapy (52.9%) and tocilizumab monotherapy (50.0%) groups than in the methotrexate monotherapy group (25.0%), with significant differences of 27.9 and 25.0 percentage points, respectively ( P < .001 for both). < .001 for both). Long-term efficacy analysis at 48 weeks showed maintained or improved efficacy in patients continuing tocilizumab monotherapy or tocilizumab-methotrexate combination therapy, with an improved disease status in those who switched to unblinded tocilizumab-methotrexate treatment at 24 weeks. Tocilizumab was well tolerated as both monotherapy and in combination with methotrexate, with no new safety signals. IN PRACTICE: 'Subcutaneous tocilizumab, both as monotherapy and in combination with methotrexate, had clinically significant efficacy compared with methotrexate monotherapy in Chinese patients with moderate to severe active RA,' the authors wrote. SOURCE: This study was led by Tian Liu, MD, Peking University People's Hospital in Beijing, China. It was published online on May 19, 2025, in JAMA Network Open . LIMITATIONS: Only Chinese patients were included, thus limiting the generalizability of the findings. Researchers did not include imaging analysis. The recruitment was extended over a period of 4 years owing to the COVID-19 pandemic, which resulted in missing the efficacy assessments and tocilizumab administration in some patients. DISCLOSURES: This study received funding from and was conducted in collaboration with F. Hoffmann-La Roche Ltd. Three authors reported receiving grants from various pharmaceutical companies, including Roche. Two authors reported being employed by Roche (China) Holding.


WIRED
an hour ago
- WIRED
Astronomers Have Detected a Galaxy Millions of Years Older Than Any Previously Observed
Jun 3, 2025 5:00 AM Researchers estimate that MoM z14 was created 280 million years after the Big Bang, 10 million years earlier than the previous most primitive galaxy recorded. The Big Bang is estimated to have taken place 13.8 billion years ago. Illustration: Getty Images With the help of the James Webb Space Telescope, a team of astronomers has broken the record for the oldest, most distant galaxy detected to date by humans. In a preprint study, still awaiting peer review and publication in a journal, astronomers describe this primitive galaxy, giving it the name MoM z14. According to the researchers' calculations, this 'cosmic miracle' originated 280 million years after the Big Bang, beating the record set by the discovery just last year of JADES-GS-Z14-0, a galaxy created 290 million years after the origin of the universe. To put these measurements in context, the current age of the universe is estimated to be 13.8 billion years. Earth has an approximate age of 4.543 billion years. No one expected the James Webb Space Telescope to have the potential to observe things so close in age to the Big Bang just three and a half years after launch. A brief reminder about distances relative to space-time. Because light travels at a finite speed of 300,000 meters per second, and because space is expanding, observing light from very distant objects is equivalent to seeing what they were like long ago. For example, when we say that MoM z14 is roughly 13.5 billion years old, that means you would have to travel 13.5 billion years at the speed of light to reach its destination. So far, there is no point detected by a scientific instrument farther away, and at the same time, older, than this one. The James Webb Space Telescope, with its ability to peer deep into distant space, allows us to study some aspects of the universe in its early stages. How does it do this? By infrared sensors. Due to the expansion of the universe, almost all the galaxies we see from Earth are moving away from us. So, from our point of view, their light appears to have a longer wavelength because it is stretched by this movement. We call this 'redshift': Their wavelengths are redder because they are longer, and so shift towards the red end of the light spectrum. The earlier an object was created, and therefore the farther away it is, having expanded outwards for a longer period of time, the greater the redshift. The James Webb Space Telescope was able to determine that MoM z14 is 50 times smaller than the Milky Way, and also detected the presence of nitrogen and carbon in the galaxy. This is significant because, despite being only 280 million years older than the Big Bang, this shows that MoM z14 does not belong to the first generation of galaxies formed, since stars in these galaxies would be made up only of hydrogen and helium, the elements that predominantly made up the early universe. Heavier elements only arrived later, after being produced in stars. Can the James Webb cross that threshold and find the first generation of galaxies? Such discoveries could be a long way off, but we have to keep looking. This story originally appeared on WIRED en Español and has been translated from Spanish.


Fox News
an hour ago
- Fox News
LIZ PEEK: Trump must stay strong, US reliance on Chinese minerals and drugs puts Americans at risk
President Donald Trump blasted China recently on Truth Social, saying Beijing had "TOTALLY VIOLATED ITS AGREEMENT WITH US." Trump furiously concluded, "So much for being Mr. NICE GUY!" Apparently, in return for mutual deescalation of trade tensions, Beijing had committed to again allow the free flow of rare earth minerals to the U.S. However, they did not follow through on that promise. No wonder Trump was angry; he should not, however, have been surprised. The White House will try to resolve this issue, and will hopefully again reduce mutual tariffs. The stock market will celebrate a near-term resolution, business managers will exhale, and shoppers won't hoard Barbies for Christmas. But longer term, the Trump White House must commit to eliminating our dependence on China for essential goods, which gives Beijing a stranglehold on our economy. China is an enemy and cannot be trusted. Relying on them for rare earths or for other critical goods, like pharmaceuticals, is dangerous. Rare earths are "essential"; we need lanthanum and cerium, for instance, to make camera lenses and catalytic converters, respectively. Indeed, we need rare earths to produce everything from cars to missiles to cell phones. China accounts for about 60% of global mine output as well as 90% of processed materials. Our economy comes to a virtual standstill without these products. The Chinese know this and will take advantage of that reliance. This is one reason that Trump's proposal of a joint venture with Ukraine is brilliant. If the two countries can together begin to mine and process rare minerals, the U.S. will have a vested interest in defending Ukraine against Russian aggression (while our presence might presumably deter another assault) and the undertaking would also help alleviate our reliance on China. Ukraine is home to 22 of the 34 minerals classified as "critical" by the EU; we need them. It is not just rare earths and minerals we should be concerned about. Since the COVID-19 emergency, Americans have become increasingly aware that we also depend on China (and to a lesser degree India) for many essential pharmaceuticals, a reliance which could prove deadly should Beijing choose to block exports. In last year's first quarter, a total of 323 drugs were in short supply, according to data published by the American Society of Health-System Pharmacists, the highest level since reporting began in 2001. The shortages sent parents searching high and low for amoxicillin and other prescription drugs for themselves and their kids. The Covid pandemic revealed the downside of not being self-sufficient in medical goods, when Beijing chose to withhold vital drugs and personal protective equipment from Americans. One of the most outrageous derelictions of Joe Biden's presidency was not addressing that dangerous vulnerability. At the outset of the pandemic, China controlled roughly half the global production of products like face masks and ventilators; though they expanded output 12-fold as Covid spread, they stopped exports to the U.S. The United States, for its part, was importing about 90% of the surgical face masks we used, even though we had invented virus-filtering N95 masks and disposable nitrile gloves. Between January and March 2020, Chinese exports of critical medical goods to the U.S. fell sharply. China apologists argue (wrongly) that the decline stemmed from tariffs placed on such goods during the first Trump administration. Ventilators, oxygen masks and other medical products were not covered by Trump's tariffs against China; the fall-off was a purposeful decision by Beijing to restrict U.S. supplies. Reacting to critical shortages, with health workers having to reuse masks and wear garbage bags over their heads for protection, U.S. firms stepped up and began producing the necessary protective gear. But, as the emergency waned, China resorted to its usual practices and flooded our market with cheap products, undercutting U.S. manufacturers. That's when the Biden administration should have stepped in to protect U.S. producers; for an administration that exhibited an almost religious zeal for wearing masks, ensuring domestic output (and availability) would seem a layup. They did not. In April 2025, the New York Times reported, "Few domestic industries have been as devastated by the flood of cheap Chinese imports as manufacturers of face masks, exam gloves and other disposable medical gear that protects healthcare workers from infectious pathogens." At the height of the pandemic, some 107 U.S. companies had started up to produce masks and glove; today only five remain. It was not just PPE that became scarce. In 2020, the New York Times quoted a Chinese health specialist at the Council on Foreign Relations saying, "Chinese pharmaceutical companies have supplied more than 90 percent of U.S. antibiotics, vitamin C, ibuprofen and hydrocortisone, as well as 70 percent of acetaminophen and 40 to 45 percent of heparin in recent years." Congress, alarmed by revelations of U.S. dependence for PPE and pharmaceuticals, did what they do best: ordered up some studies on the issue and demanded better reporting. During Trump's last year in office, his administration tried to boost domestic manufacturing of pharmaceuticals, but the effort died in the Biden years. In last year's first quarter, a total of 323 drugs were in short supply, according to data published by the American Society of Health-System Pharmacists, the highest level since reporting began in 2001. This is a fixable problem. If we can devote hundreds of billions of dollars to boosting domestic production of windmills and semiconductors, surely we should be taking similar steps to end our dependence on Chinese-provided drugs. The New York Times revealed the Biden administration's multi-billion-dollar solution to drug shortages writing, "The White House earlier this month proposed… linking Medicare payments to hospitals in part on whether hospitals do a good job buying drugs from companies that demonstrate quality over the long term, rather than just the cheapest price." That is not a solution. Instead, a solution would entail reducing our dependence on China for essential goods of all kinds and making domestic manufacturing profitable again through lower taxes, new technology like AI and deregulation. These are policies that dominate the Trump agenda, and they will work to make the U.S. independent again.